Sensorion S.A.
SENOF
Other OTC2.73
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
18.86
3Y
- -
64.57
5Y
- -
71.65
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Address
- Similar Companies
- Business
- Sensorion SA (SENOF), a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Montpellier, France, develops novel therapies to restore, treat, and prevent inner ear disorders including hearing loss and vestibular pathologies. The company's pipeline encompasses gene therapies such as OTOF-GT (SENS-501) in Phase 1/2 for otoferlin deficiency, with data monitoring for cohorts 1 and 2 expected by end of H2 2025; GJB2-GT in preclinical CTA/IND-enabling activities for GJB2-related hearing loss across pediatric progressive, congenital, and early presbycusis indications; and small-molecule SENS-401 programs, including SENS-401 SSNHL following Phase 2b completion for sudden sensorineural hearing loss with partnering options under exploration, SENS-401 CIO in Phase 2a for cisplatin-induced ototoxicity with topline data due end of H2 2025, and SENS-401 Cochlear in Phase 2a for hearing preservation post-cochlear implantation where primary endpoint was met. Sensorion operates primarily in Europe through its R&D platform focused on inner ear pathophysiology, targeting patients with genetic and non-genetic hearing impairments. In February 2024, the company raised €50.5 million in a reserved offering from investors including Redmile Group, Invus, Sofinnova Partners, and new U.S. healthcare funds like Aquilo Capital, extending cash runway to Q2 2025 to advance gene therapy collaborations with Institut Pasteur and support SENS-501's Audiogene Phase 1/2 trial initiation in Europe; recent July 2024 data from SENS-401 Phase II further demonstrated potential for residual hearing preservation.